Global Health Ventures Receives the First Shipment of Its Commercially Manufactured Male Enhancement Drug “X-Excite”
Stuart Smith (November 9th, 2009) Writes:
VANCOUVER, BRITISH COLUMBIA — (Marketwire) — 11/09/09 — Global Health Ventures Inc. (OTCBB: GHLV), or the “Company” a Specialty Pharma is pleased to announce today that it has completed the prototype manufacturing of the drug “X-Excite” Global’s male enhancement drug. The manufacturing of the product was carried out under contract with Vida Pharma of Montreal, Canada. Vida Pharma specialized in the designing of the new tablet size, taste, and hardness. The Company has manufactured over 4000 pills from several different incipient and coatings that are all safe for human consumption. These various batches will be tested at the University of British Columbia, Canada for independent evaluation in regards to drugs adsorption, taste, color and hardness. If the samples meet our end goals then the drug will be ready for mass production under the proprietary formula for testing in humans and finally applying for regulatory approval.
The Company plans to
...British Columbia, Canada, Europe, Global Health Ventures Inc., Investing Lessons, Life style products, life-style pharmaceutical product, male enhancement drug, Montreal, Pharmaceutical, Pharmaceuticals, Platform Technology, President and CEO, Salari, Small & Micro Cap, smallcapvoice, United States, University of British Columbia, USD, VANCOUVER, Vida Pharma


![[Most Recent Quotes from www.kitco.com]](http://www.kitconet.com/charts/metals/gold/t24_au_en_usoz_2.gif)
![[Most Recent Quotes from www.kitco.com]](http://www.kitconet.com/charts/metals/silver/t24_ag_en_usoz_2.gif)

Figure 1: Log nominal value of US dollar (blue) and real value of US dollar (red), against currencies of major trading partners. NBER defined recession dates shaded gray, assuming the recession has not ended by July 2009. Source: Federal Reserve Board.




